Provisio Medical Technologies Corp — SEC Form D Filing
Provisio Medical Technologies Corp filed an SEC Form D on August 6, 2026, reporting $50K raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 6, 2026
- Amount reported
- $50K
- Round stage
- Seed
- Industry
- Medical Devices
- Website
- https://provisiomedical.com/
What the company does
Securities: Debt in form of convertible note into shares of a to be designated senior preferred stock of Issuer on terms to be determined.. Exemption: Rule 506(c). Incorporated: DELAWARE
Problem
Peripheral Artery Disease (PAD) affects 200 million people worldwide and has a high mortality rate, often leading to major amputations. Existing diagnostic tools like angiograms and traditional IVUS are inadequate, underestimating vessel size and requiring additional procedures, leading to a diagnostic gap.
Solution
Provisio Medical Technologies is developing the SLT Platform, including SLT FLOW™ and SLT IVUS® P1 System, which are automated, integrated smart-catheter technologies. These technologies provide real-time, accurate numeric measurements of the flow lumen of blood vessels, including volumetric blood flow (perfusion), without image interpretation or delay.
Why now
Current diagnostic tools for Peripheral Artery Disease, such as angiograms and traditional IVUS, are insufficient and consistently underestimate vessel size, leading to limited improvements from existing therapies. There is a need for more precise, integrated, intra-procedural diagnostic intelligence.
Verdict
Investors backed a niche diagnostic improvement within an established medical device market, implicitly betting on clinical adoption driven by clearer, quantifiable data over the subjective interpretation of existing imaging. This cleared because it offered a tangible incremental improvement to a high-stakes procedure, not because it promised a disruptive shift in PAD treatment paradigms. The limited upside stemmed from the technology's integration into existing procedural workflows, which constrained its potential to capture a larger share of the overall care pathway.
Source: SEC EDGAR Form D filing